Literature DB >> 2897363

Arginine for glycine substitution in the triple-helical domain of the products of one alpha 2(I) collagen allele (COL1A2) produces the osteogenesis imperfecta type IV phenotype.

R J Wenstrup1, D H Cohn, T Cohen, P H Byers.   

Abstract

Skin fibroblasts from two affected members of a family with an autosomal dominant form of mild-moderate osteogenesis imperfecta produced two populations of type I collagen molecules. One population was normal and the other population contained alpha 2(I) chains which had a basic charge shift localized to a peptide from the carboxyl-terminal end of the triple-helical domain. The alpha chains in the abnormal molecules had increased post-translational modification along the entire triple-helical domain but the thermal stability was normal. We isolated a 28-kb BamHI fragment from the normal and mutant COL1A2 alleles from an affected family member. DNA sequence determination demonstrated that a single nucleotide change resulted in an arginine for glycine substitution at triple-helical position 1012, the last triple-helical glycine. These data demonstrate the stringent requirement for maintenance of the Gly-X-Y triplet sequence in type I collagen and suggest that point mutations which disrupt Gly-X-Y in alpha 2(I) produce milder clinical effects than similar mutations in alpha 1(I).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897363

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  A single base mutation in type I procollagen (COL1A1) that converts glycine alpha 1-541 to aspartate in a lethal variant of osteogenesis imperfecta: detection of the mutation with a carbodiimide reaction of DNA heteroduplexes and direct sequencing of products of the PCR.

Authors:  J P Zhuang; C D Constantinou; A Ganguly; D J Prockop
Journal:  Am J Hum Genet       Date:  1991-06       Impact factor: 11.025

Review 2.  Osteogenesis imperfecta: translation of mutation to phenotype.

Authors:  P H Byers; G A Wallis; M C Willing
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

3.  The clinical features of three babies with osteogenesis imperfecta resulting from the substitution of glycine by arginine in the pro alpha 1(I) chain of type I procollagen.

Authors:  W G Cole; C W Chow; J G Rogers; J F Bateman
Journal:  J Med Genet       Date:  1990-04       Impact factor: 6.318

4.  A lethal variant of osteogenesis imperfecta has a single base mutation that substitutes cysteine for glycine 904 of the alpha 1(I) chain of type I procollagen. The asymptomatic mother has an unidentified mutation producing an overmodified and unstable type I procollagen.

Authors:  C D Constantinou; K B Nielsen; D J Prockop
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

5.  Type II achondrogenesis-hypochondrogenesis: identification of abnormal type II collagen.

Authors:  M Godfrey; D W Hollister
Journal:  Am J Hum Genet       Date:  1988-12       Impact factor: 11.025

Review 6.  The triple helix of collagens - an ancient protein structure that enabled animal multicellularity and tissue evolution.

Authors:  Aaron L Fidler; Sergei P Boudko; Antonis Rokas; Billy G Hudson
Journal:  J Cell Sci       Date:  2018-04-09       Impact factor: 5.285

7.  Proliferation of rabbit chondrocyte and inhibition of IL-1β-induced apoptosis through MEK/ERK signaling by statins.

Authors:  Bin Zhou; Deheng Chen; Huazi Xu; Xiaolei Zhang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-10-03       Impact factor: 2.416

8.  Cysteine in the triple helical domain of the pro alpha 2(I) chain of type-I collagen in nonlethal forms of osteogenesis imperfecta.

Authors:  D H Cohn; P H Byers
Journal:  Hum Genet       Date:  1991-06       Impact factor: 4.132

9.  Frameshift mutation near the 3' end of the COL1A1 gene of type I collagen predicts an elongated Pro alpha 1(I) chain and results in osteogenesis imperfecta type I.

Authors:  M C Willing; D H Cohn; P H Byers
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

10.  Distinct biochemical phenotypes predict clinical severity in nonlethal variants of osteogenesis imperfecta.

Authors:  R J Wenstrup; M C Willing; B J Starman; P H Byers
Journal:  Am J Hum Genet       Date:  1990-05       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.